Most people with MS who are treated with formulations of botulinum toxin to manage spasticity report being satisfied, a study ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chronic pain, epilepsy, and inflammatory conditions.

Synthetic cannabinoids, a class of new psychoactive substances, have emerged as a significant public health and social stability threat due to their structural diversity, rapid iteration, and stronger ...

For example, multiple hemp shop operators in Austin have told the Chronic that customers who buy CBD oil for therapeutic use ...

As patients increasingly turn to cannabis for chronic pain, clinicians grapple with mixed evidence and a lack of high-quality ...

Since cultivation of cannabis was legalised in Australia in 2016 for medical purposes (and only with a license), there’s been a surging interest in the product. And not just from the public. Worth an ...

Differentiated Therapeutic Profile: These findings underscore ART12.11’s potential as a highly differentiated candidate for treating depression and anxiety, especially in patients where cognitive ...

Teen vaping habits are shifting toward stronger and more mysterious substances. Synthetic cannabinoids are rising fast — and ...

RSO is more than just another cannabis product. It’s a full-spectrum, whole-plant extract with a serious reputation – especially among people using it for therapeutic purposes. And that’s all a […] ...

Novel research has revealed that adolescent vaping of current delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and ...

Catching up with Betty's Eddies Brand Ambassador Sara Rosenfield to discuss the brand's seasonal summer product and more.